Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 36Nivolumab 32Bevacizumab 13Sunitinib 10Ipilimumab 10aldesleukin 7Interleukin-2 7Axitinib 7lenvatinib 6cabozantinib 6Paclitaxel 6Everolimus 6Docetaxel 6Cyclosporine 6Cyclophosphamide 6fludarabine phosphate 5Sorafenib 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5fludarabine 4cemiplimab 4belzutifan 4Whole-Body Irradiation 4Radiosurgery 4Interferon-alpha 4Cetuximab 4durvalumab 3bempegaldesleukin 3avelumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Renal Cell × HBI-8000 × Clear all
NCT02718066 2023-11-09

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

HUYABIO International, LLC.

Phase 1/2 Completed
96 enrolled
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡